New York is currently home to 4507 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
RESTORE - Phase II
Recruiting
The study will apply the principles of Community Based Participatory Research to evaluate implementation strategies, designed to assist in the delivery of an evidence-based lifestyle counseling intervention for pregnant participants. The primary strategies include a technology supported strategy (low touch) in which text messaging and online videos are used for asynchronous viewing compared to a Community Health Worker-led synchronous (group and individual) strategy (high touch). Prior to implem... Read More
Gender:
FEMALE
Ages:
Between 18 years and 89 years
Trial Updated:
03/20/2025
Locations: NYC Health + Hospitals/Bellevue, New York, New York
Conditions: Maternal Health
Ribociclib and Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
Recruiting
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: New York University Clinical Cancer Center, New York, New York
Conditions: Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
A Study of YL201 in Patients with Advanced Solid Tumors
Recruiting
This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2). Part 1 will estimate the MTD/RED(s) in dose escalation cohorts of patients with advanced solid tumors unresponsive to currently available therapies or for whom no standard therapy is available. Part 2 will include patients with selected advanced solid tumor t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Advanced Solid Tumor
Cephea Early Feasibility Study
Recruiting
The objective of this study is to evaluate the preliminary safety and effectiveness of the Cephea Mitral Valve System for the treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) in whom transcatheter therapy is deemed more appropriate than open heart surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Mitral Regurgitation
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
Recruiting
The purpose of this study is learn more about how being treated for breast cancer affects patients' employment. Researchers are testing an early version of a mobile app designed to help breast cancer patients keep their jobs during and after treatment. The app provides advice for patients to use when having conversations about breast cancer with their employers and their doctors. The app is called TEAMWork (Talking to Employers And Medical staff about Work). In this study, the investigators are... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Lincoln Medical and Mental Health Center, Bronx, New York
Conditions: Breast Cancer
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
Recruiting
This study will use PET scans, which is a type of x-ray test that uses a radiotracer, to see whether these scans may be better able to find places in the body where your prostate cancer may have spread.
Gender:
MALE
Ages:
All
Trial Updated:
03/20/2025
Locations: Memorial Sloan Kettering Commack (Consent only), Commack, New York
Conditions: Prostate Cancer
Pleuroscopy First Versus Thoracentesis First in Patients with Suspected Malignant Pleural Effusions
Recruiting
This is a randomized control trial of patients with suspected malignant pleural effusions to compare whether patients who have a thoracentesis or pleuroscopy (pleural biopsy) obtain an adequate biopsy, achieve a diagnosis, and begin cancer-directed therapy faster.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Mount Sinai West, New York, New York
Conditions: Pleural Effusion, Cancer
THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
Recruiting
The primary objective of the THRIVE Pivotal study is to demonstrate the adjunctive effectiveness and the safety of the TIVUS system in: 1. subjects with hypertension (HTN) receiving up to 2 anti-hypertensive drugs of different classes in whom the anti-hypertensive medications will be stopped for a 4-week wash-out period before RDN/Sham procedure and during 2 months after procedure. 2. subjects with controlled hypertension receiving up to 2 anti-hypertensive drugs of different classes and who ac... Read More
Gender:
ALL
Ages:
Between 22 years and 75 years
Trial Updated:
03/19/2025
Locations: Nyph/Cumc, New York, New York
Conditions: Hypertension
Thermogenic Silencer Regulatory Factors in Humans
Recruiting
A promising approach to correct the metabolic dysfunction associated with obesity is to activate brown fat non-shivering thermogenesis (NST). A critical limitation with NST as a therapeutic option, however, is that this beneficial process is silenced under human physiological temperature conditions and the mechanisms of how this occurs is unknown. This study will be the first to identify human NST silencing factors that may be targeted for the treatment of obesity and metabolic disorders.
Gender:
ALL
Ages:
Between 18 years and 35 years
Trial Updated:
03/19/2025
Locations: Rockefeller University, New York, New York
Conditions: Obesity, Metabolic Disease, Cold Exposure
An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers
Recruiting
This clinical trial evaluates the impact of an education and navigation support tool (ENST) on patient and caregiver participation in care coordination for bladder cancer that has spread to nearby tissue or lymph nodes (locally advanced), to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Patients with advanced bladder cancer tend to be older, have multiple medical conditions and often have poor access to health care. An ENST may be an effective method... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Locally Advanced Bladder Carcinoma, Metastatic Bladder Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Unresectable Bladder Carcinoma
MedSupport Intervention to Identify and Address Barriers to Pediatric Medication Adherence
Recruiting
This clinical trial identifies and addresses barriers to pediatric medication adherence among families of children with acute lymphoblastic leukemia. Pediatric nonadherence (noncompliance) to medication is a significant public health problem, and rigorous research repeatedly documents that nonadherence increases risk for hospitalization, healthcare cost, disease progression, and death. Pediatric acute lymphoblastic leukemia (ALL) patients who miss 5% of 6-mercaptopurine (6-MP) doses within the 2... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/19/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Acute Lymphoblastic Leukemia
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab for Patients Who Are Disease Free After Completion of Trimodality Treatment for HER-2+ Cancers of Esophagus & Gastroesophageal Junction
Recruiting
An open label phase II study to determine the safety and preliminary efficacy of the combination of 1-year of adjuvant trastuzumab deruxtecan and nivolumab for patients with HER2 overexpressing esophagogastric adenocarcinoma who have completed chemoradiation followed by esophagectomy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Weill Cornell Medicine/New York-Presbyterian, New York, New York
Conditions: Esophageal Adenocarcinoma, Esophageal Cancer, HER-2 Protein Overexpression, Gastroesophageal-junction Cancer